| 1 |
34945777 | Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study. | 2021 Dec 5 |
2 |
| 2 |
31628422 | Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers. | 2020 Apr |
2 |
| 3 |
32838647 | Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China. | 2020 Aug |
1 |
| 4 |
24497997 | Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. | 2014 |
1 |
| 5 |
22297387 | Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. | 2012 Mar |
1 |
| 6 |
23082557 | Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy. | 2012 Jan |
1 |
| 7 |
23133441 | ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients. | 2012 |
1 |
| 8 |
20660679 | No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. | 2010 Oct |
1 |
| 9 |
17047492 | Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. | 2006 Nov |
1 |
| 10 |
15718846 | The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. | 2005 Feb 18 |
2 |
| 11 |
14711599 | No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. | 2003 Dec 9 |
1 |